Phantom Neuro — Spinal & Peripheral Interfaces · fobi

Phantom Neuro

Develops peripheral nerve interfaces and implantable devices for prosthetic control and sensory feedback. Spun out of University of Alberta. Raised seed funding and working on preclinical and early clinical validation for upper-limb prosthetic applications.

Targeting the prosthetics and limb-restoration market with high-fidelity peripheral nerve recording, an alternative pathway to motor BCI via peripheral rather than cortical interfaces.

phantomneuro.com Spinal & Peripheral Interfaces

Canadaprivate

At a glance

Total raised

$28.3M

last round series a

Headcount

11-50

approximate · public range

Headquarters

Edmonton

Canada

Founded

2020

6 years active

Status

Private

Spinal & Peripheral Interfaces

Subsector

For subscribers

Subscribe to see the full profile

Including Funding rounds, Bull / Bear thesis, Stock + earnings, Roster changes, Patents, News, and Open roles.

Already subscribed? Sign in →

Date	Stage	Amount	Valuation	Lead investors
Mar 1, 2025	Series A	$19M	—	Ottobock
Sep 1, 2022	Seed	$6M	—	Time BioVentures

AI bull / bear

Bull case

Peripheral nerve interfaces offer a pragmatic middle path between non-invasive wearables and full craniotomy-based BCIs. By targeting the peripheral rather than cortical nervous system, Phantom Neuro avoids the surgical complexity, infection risk, and regulatory scrutiny of penetrating brain implants while still delivering high-fidelity motor and sensory signals. That positioning could unlock faster clinical translation for prosthetic applications. The University of Alberta spinout pedigree suggests deep neural-engineering expertise, and the focus on upper-limb prosthetics addresses a clear unmet need: amputees currently have few options beyond basic myoelectric sleeves with limited dexterity. High-fidelity peripheral nerve recording would be a genuine leap forward in signal resolution compared to surface EMG. If Phantom Neuro can deliver even modest preclinical validation of stable, long-term recording from peripheral nerves, the technology becomes an attractive acquisition target for larger prosthetics or neurostimulation players looking to add closed-loop control capabilities without taking on cortical-implant risk.

Bear case

Phantom Neuro remains at the preclinical and seed stage with no disclosed funding amount, making it difficult to assess whether the company has sufficient capital to reach first-in-human data, let alone commercial approval. Peripheral nerve interfaces face a well-documented biological obstacle: even high-fidelity recording electrodes degrade over time due to encapsulation, fibrosis, and micromotion, a problem that has plagued the field for decades. No company has yet commercialized a chronic peripheral nerve interface for prosthetics at scale. Meanwhile, the company must compete with cortical BCI players who have billions in funding and are actively targeting the same motor-restoration use case, as well as advanced myoelectric prosthetics that improve year over year without any implant. The prosthetics market itself is relatively small, and payers are notoriously resistant to covering implantable devices with uncertain durability. Without a clear regulatory strategy or published clinical data, Phantom Neuro remains a lab-stage concept in a capital-intensive field where many promising approaches have stalled before reaching patients.

Generated by deepseek-v4-flash · June 2, 2026Refreshes quarterly · see disclosures

Phantom Neuro

At a glance

Subscribe to see the full profile

Funding history

How they make money

Founder backgrounds

Connor Glass

AI bull / bear

In the news

Leadership

Products

Phantom X Neural Interface

Open roles

Compare Phantom Neuro with